Korean Stock Flows

SK Biopharmaceuticals (KRX: 326030)

SK바이오팜 KOSPI Biotech & Pharma 자연과학 및 공학 연구개발업
Close (Oct 16, 2026)
₩73,300
+5.62%
Market cap
₩6T ($4.3B)
52-week range
₩67,800 – ₩144,100
P/E (12M fwd) · P/B · Div yield
14.67 · 7.06 · 0%
trailing 21.50 · consensus of 11 analysts

Who is buying SK Biopharmaceuticals?

Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net sold ₩30.6bn ($23M) of SK Biopharmaceuticals, the 67th largest foreign net sale among 832 KOSPI stocks. Institutions net bought ₩3.3bn ($2M) and retail investors net bought ₩26.3bn ($20M) over the same window. Foreigners were net buyers on 6 of the 20 sessions.

Foreign investors hold 11.66% of SK Biopharmaceuticals' listed shares (KRX ownership data as of Oct 16, 2026), down from 12.08% twenty sessions earlier and 11.1% a year ago.

The stock closed at ₩73,300 on Oct 16, 2026: -7.33% over 20 sessions, -41.17% year-to-date, -28.70% over one year. The 52-week range is ₩67,800 – ₩144,100.

At ₩73,300 the stock trades at 14.67× 12-month-forward consensus earnings (11 analysts), 14.10× on FY2027 estimates. The trailing P/E published by KRX is 21.50×, based on the last completed fiscal year.

SK Biopharmaceuticals share price, last 60 trading days (KRW)
92,932 84,644 76,356 68,068 Jul 16 Aug 31 Oct 16
Daily foreign investor net purchases, last 60 trading days
+7.9bn +4bn -4bn -7.9bn Jul 16 Aug 31 Oct 16
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-16 ₩73,300 +₩3.2bn +₩1.7bn ₩-4.4bn
2026-10-15 ₩69,400 ₩-1.0bn +₩3.3bn ₩-2.3bn
2026-10-14 ₩70,300 +₩0.8bn ₩-0.3bn ₩-0.3bn
2026-10-13 ₩70,700 +₩0.3bn +₩1.0bn ₩-1.4bn
2026-10-12 ₩71,000 +₩0.1bn +₩0.7bn ₩-0.8bn
2026-10-08 ₩72,700 ₩-3.9bn ₩-2.5bn +₩5.9bn
2026-10-07 ₩76,000 ₩-2.0bn ₩-0.5bn +₩2.6bn
2026-10-06 ₩76,600 ₩-3.2bn +₩0.6bn +₩2.6bn
2026-10-02 ₩75,800 ₩-2.6bn +₩0.2bn +₩2.4bn
2026-10-01 ₩76,700 +₩0.3bn +₩0.4bn ₩-0.6bn
2026-09-30 ₩74,400 ₩-1.1bn +₩0.1bn +₩1.0bn
2026-09-29 ₩74,900 ₩-3.5bn ₩-0.4bn +₩3.2bn
2026-09-28 ₩76,200 ₩-0.4bn ₩-0.7bn +₩1.1bn
2026-09-23 ₩75,900 ₩-4.2bn +₩0.0bn +₩3.7bn
2026-09-22 ₩76,900 ₩-3.1bn +₩0.1bn +₩2.9bn
2026-09-21 ₩77,600 ₩-2.1bn +₩0.7bn +₩1.4bn
2026-09-18 ₩77,700 ₩-7.3bn +₩0.7bn +₩6.5bn
2026-09-17 ₩79,200 ₩-1.2bn +₩0.4bn +₩0.9bn
2026-09-16 ₩78,200 +₩1.4bn ₩-0.6bn ₩-0.6bn
2026-09-15 ₩78,100 ₩-0.9bn ₩-1.5bn +₩2.6bn
2026-09-14 ₩79,100 +₩0.2bn ₩-0.5bn +₩0.3bn
2026-09-11 ₩79,400 ₩-3.3bn ₩-5.4bn +₩8.4bn
2026-09-10 ₩83,400 ₩-2.1bn +₩1.1bn +₩0.8bn
2026-09-09 ₩83,800 +₩1.2bn ₩-1.5bn +₩0.3bn
2026-09-08 ₩83,200 ₩-2.7bn ₩-1.9bn +₩4.5bn
2026-09-07 ₩85,000 ₩-6.8bn +₩1.8bn +₩4.8bn
2026-09-04 ₩86,600 ₩-1.0bn +₩0.3bn +₩0.4bn
2026-09-03 ₩86,400 +₩0.8bn ₩-2.1bn +₩0.8bn
2026-09-02 ₩86,300 ₩-0.1bn ₩-1.3bn +₩1.3bn
2026-09-01 ₩89,000 ₩-2.1bn +₩1.6bn +₩0.3bn
2026-08-31 ₩87,300 ₩-0.6bn ₩-0.1bn +₩0.6bn
2026-08-28 ₩88,000 ₩-2.9bn +₩0.7bn +₩2.1bn
2026-08-27 ₩88,000 ₩-7.9bn ₩-0.2bn +₩8.0bn
2026-08-26 ₩91,600 ₩-2.0bn +₩9.9bn ₩-7.5bn
2026-08-25 ₩84,400 ₩-2.1bn ₩-0.3bn +₩2.4bn
2026-08-24 ₩86,400 +₩1.8bn +₩0.9bn ₩-2.6bn
2026-08-21 ₩83,700 ₩-2.9bn +₩0.3bn +₩2.4bn
2026-08-20 ₩86,500 ₩-0.4bn ₩-1.3bn +₩1.6bn
2026-08-19 ₩85,300 +₩1.2bn ₩-1.0bn ₩-0.1bn
2026-08-18 ₩85,200 ₩-0.3bn ₩-1.0bn +₩1.3bn
2026-08-14 ₩87,300 ₩-2.7bn ₩-0.3bn +₩3.0bn
2026-08-13 ₩87,600 +₩3.0bn ₩-4.5bn +₩1.3bn
2026-08-12 ₩88,200 ₩-2.3bn ₩-0.6bn +₩3.0bn
2026-08-11 ₩90,500 +₩1.5bn +₩0.8bn ₩-3.1bn
2026-08-10 ₩88,700 +₩1.7bn +₩1.6bn ₩-3.4bn
2026-08-07 ₩85,400 +₩2.5bn +₩1.7bn ₩-4.1bn
2026-08-06 ₩83,500 ₩-1.5bn +₩1.4bn ₩-0.0bn
2026-08-05 ₩82,000 ₩-2.7bn +₩2.5bn +₩0.2bn
2026-08-04 ₩79,800 +₩1.3bn ₩-0.8bn +₩0.3bn
2026-08-03 ₩78,400 +₩0.6bn ₩-1.2bn +₩1.3bn
2026-07-31 ₩79,000 +₩0.0bn ₩-2.3bn +₩3.2bn
2026-07-30 ₩77,600 +₩4.7bn +₩1.2bn ₩-4.8bn
2026-07-29 ₩75,600 ₩-1.7bn +₩2.2bn +₩0.4bn
2026-07-28 ₩79,500 +₩1.3bn +₩1.4bn ₩-2.4bn
2026-07-27 ₩81,900 +₩0.4bn ₩-0.3bn ₩-0.0bn
2026-07-24 ₩80,600 +₩2.5bn ₩-0.5bn ₩-2.0bn
2026-07-23 ₩79,700 +₩0.3bn ₩-0.3bn ₩-0.7bn
2026-07-22 ₩76,800 ₩-0.5bn ₩-1.2bn +₩0.7bn
2026-07-21 ₩77,600 +₩2.6bn ₩-1.9bn ₩-1.5bn
2026-07-20 ₩76,800 ₩-1.8bn +₩1.1bn ₩-0.1bn
2026-07-16 ₩79,400 +₩0.2bn +₩0.9bn ₩-1.7bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day +₩3.2bn +$2M +₩1.7bn ₩-4.4bn
5 days +₩3.3bn +$2M +₩6.4bn ₩-9.2bn
20 days ₩-30.6bn $-23M +₩3.3bn +₩26.3bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying SK Biopharmaceuticals stock?

Over the last 5 sessions foreign investors net bought ₩3.3bn ($2M) of SK Biopharmaceuticals; over 60 sessions they net sold ₩53.6bn ($40M); since Jan 1, 2026 they net sold ₩99.8bn ($74M). Over 20 sessions the stock is the 67th largest foreign net sale among 832 KOSPI stocks.

How much of SK Biopharmaceuticals do foreign investors own?

Foreign investors own 11.66% of SK Biopharmaceuticals' shares as of Oct 16, 2026, versus 11.1% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net bought ₩3.3bn ($2M) and retail investors net bought ₩26.3bn ($20M) of SK Biopharmaceuticals. Foreign selling is being absorbed mainly by retail buying.

Is SK Biopharmaceuticals listed on KOSPI or KOSDAQ?

SK Biopharmaceuticals (SK바이오팜) trades on KOSPI under KRX code 326030 in the Biotech & Pharma group, with a market capitalization of ₩6T ($4.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩355bn ($264M) – -₩38bn (-$28M) -₩35bn (-$26M)
2024 ₩548bn ($407M) +54.30% ₩96bn ($72M) ₩227bn ($169M)
2025 ₩707bn ($525M) +29.10% ₩204bn ($152M) ₩253bn ($188M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.

← All foreign investor flows